Latest News about ABBV
Recent news which mentions ABBV
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
October 03, 2024
From Benzinga
5 Best Dividend Growth Stocks to Buy in October
October 02, 2024
From Motley Fool
From Benzinga
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
September 27, 2024
From Benzinga
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
September 26, 2024
From Benzinga
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease
September 26, 2024
From Benzinga
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
September 26, 2024
From Motley Fool
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
September 20, 2024
From Benzinga
Spotlight on AbbVie: Analyzing the Surge in Options Activity
September 20, 2024
Tickers
ABBV
From Benzinga
From Benzinga
From Motley Fool
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
September 17, 2024
From Benzinga
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
September 16, 2024
From Motley Fool
Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More
September 14, 2024
From Motley Fool
3 Stocks to Buy and Hold Forever
September 14, 2024
From Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
September 14, 2024
From Motley Fool
Is This Company Still a Strong Buy After Tripling the S&P 500's Returns?
September 13, 2024
Tickers
ABBV
From Motley Fool
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.